Lung adenocarcinoma–derived IFN-γ promotes growth by modulating CD8+ T cell production of CCR5 chemokines
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci191070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Christina Kratzmeier und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Maryland, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Interferon-gamma, Receptors, CCR5, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Because the lung is a mucosal barrier organ with a unique immunologic environment, mechanisms of immunoregulation in lung cancer may differ from those of other malignancies. Consistent with this notion, we found that CD8 + T cells played a paradoxical role in facilitating, rather than ameliorating, the growth of multiple lung adenocarcinoma models. These included spontaneous, carcinogen-induced, and transplantable tumor cell line models. Specifically, we found that CD8 + T cells promoted homing of CD4 + Foxp3 + Tregs to the tumor bed by increasing the levels of CCR5 chemokines in the tumor microenvironment in an IFN-γ– and TNF-α–dependent manner. Contrary to their canonical role, these Th1 cytokines contributed to accelerated growth of murine lung adenocarcinomas, while suppressing the growth of other malignancies. Surprisingly, lung cancer cells themselves can serve as a dominant source of IFN-γ, and deletion of this cytokine from cancer cells using CRISPR/Cas9 decreases tumor growth. Importantly for translational applications, in patients with lung cancer, a high level of IFN-γ was also found at both the mRNA and protein levels. Our data outline what we deem a novel and previously undefined lung cancer–specific immunoregulatory pathway that may be harnessed to tailor immune-based therapy specifically for this malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Maryland, Baltimore, Maryland, USA.
- Department of Microbiology and Immunology, University of Maryland, School of Medicine, Baltimore, Maryland, USA.
- Department of Medicine, University of Maryland, Baltimore, Maryland, USA.
- University of Maryland, Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
- Department of Anatomical Pathology, University of Maryland, Baltimore, Maryland, USA.
- Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA.
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- NHLBI NIH HHS
- BLRD VA
- NIH NIAID
- NIH NHLBI
- Veterans Affairs
- NIH NCI
Zitieren
APA
Kratzmeier, C., Taheri, M., Mei, Z., Lim, I., Khalil, M. A., Carter-Cooper, B., Fanaroff, R. E., Ong, C. S., Schneider, E. B., Chang, S., Leyder, E., Li, D., Luzina, I. G., Banerjee, A., & Krupnick, A. S. (2025). Lung adenocarcinoma–derived IFN-γ promotes growth by modulating CD8+ T cell production of CCR5 chemokines. Journal of Clinical Investigation. https://doi.org/10.1172/jci191070
Vancouver
Kratzmeier C, Taheri M, Mei Z, Lim I, Khalil MA, Carter-Cooper B, et al. Lung adenocarcinoma–derived IFN-γ promotes growth by modulating CD8+ T cell production of CCR5 chemokines. Journal of Clinical Investigation. 2025. doi:10.1172/jci191070
BibTeX
@article{Kratzmeier2025,
author = {Kratzmeier, Christina and Taheri, Mojtaba and Mei, Zhongcheng and Lim, Isabelle and Khalil, May A and Carter-Cooper, Brandon and Fanaroff, Rachel E and Ong, Chin Siang and Schneider, Eric B and Chang, Stephanie and Leyder, Erica and Li, Dongge and Luzina, Irina G and Banerjee, Anirban and Krupnick, Alexander Sasha},
title = {Lung adenocarcinoma–derived IFN-γ promotes growth by modulating CD8+ T cell production of CCR5 chemokines},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci191070}
}
EUVIMED